Abstract: Objective : There is currently no standard salvage regimen for patients with recurrent and refractorynon-Hodgkin's lymphoma (NHL). This study investigated the efficacy of the DICE (dexamethasone, isofos-famide, cisplatin, and etoposide) regimen on recurrent and refractory NHL and observed the correspondingadverse events. Methods : We reviewed the clinical records of 22 patients with recurrent and refractory NHLwho failed to achieve remission after 2-6 cycles of CHOP regimen and received DICE as a salvage regimenwith a median of 4 cycles (range 2-7 cycles). Of the 22 patients, 8 patients had malignancies originating fromT-cells, and the other 14 had malignancies originating from B-cells. The efficacy of the DICE regimen and itsadverse events were evaluated. Results : The total response rate (RR) of these 22 patients was 63.6%. Thecomplete remission (CR) rate was 40.9%. The response rate was 75.0% for T-cell NHL and 57.1% for B-cellNHL. The CR rate was 37.5% for T-cell NHL and 42.9% for B-cell NHL (P>0.05). Elevated serum levels of lac-tate dehydrogenase (LDH) and the presence of bulky disease were risk factors for the efficacy of the DICEregimen (P<0.05). Major adverse events included myelosuppression, nausea, vomiting, and alopecia, andthese adverse effects could be treated. No chemotherapy-related death occurred. Conclusion : The DICE regi-men is effective for treating recurrent and refractory NHL.